2-Aminoindane

Argentina treats substances falling within the aminoindane chemical group in Annex II of Decree 560/2019 as estupefacientes under Penal Code article 77. The Annex II structure and substituent rules cover the parent 2-aminoindane scaffold, while the group provision also extends to enantiomers, diastereomers, and their salts. Decree 122/2026 replaces only Annex I, so the Annex II aminoindane group remains the applicable blanket control.

Australian state law expressly lists 2-aminoindane as a prohibited drug. The NSW Act makes possession, manufacture, supply and self-administration of a Schedule 1 prohibited drug offences, subject to authorised or prescribed exceptions.

Prohibited under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act). Possession, production, and sale are all illegal.

Belgium places nationally listed amphetamine derivatives in Annex IVa of the Royal Decree of 6 September 2017 regulating narcotic and psychotropic substances. The annex defines derivatives of 1-phenylpropan-2-amine and permits the CnH2n+1 side-chain element to be incorporated into a ring structure linked to the phenyl or amine; 2-aminoindane (2,3-dihydro-1H-inden-2-amine) is the corresponding ring-closed scaffold. The AFMPS explains that Annex IVa uses a generic structural classification, so coverage is not limited to substances printed by name in its indicative list.

Classified as a controlled substance since October 2015.

The current Danish regulation expressly lists 2-aminoindan (2,3-dihydro-1H-inden-2-amin). Euphoriants may be used only for medical or scientific purposes under section 3, with handling restricted to authorised persons and institutions.

Scheduled under the government decree on psychoactive substances banned from the consumer market.

Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since November 26, 2016. Production and import with intent to distribute, administration to others, and trading are punishable offenses. Possession is prohibited but not subject to criminal penalties.

2-Aminoindane is the named substance 2,3-dihydro-1H-inden-2-amine. The 2017 Regulations came into operation on 4 May 2017 and Regulation 5(1) prohibits producing, supplying or offering to supply, and importing or exporting a controlled drug, subject to the Regulations. Schedule 1 paragraph 1(o) expressly names 2,3-dihydro-1H-inden-2-amine and covers specified phenyl-ring and nitrogen substitutions; paragraphs 2 to 5 extend coverage to stereoisomers, esters or ethers, salts, and preparations or other products containing covered substances. S.I. No. 121/2021 substituted Schedule 1 and retained the exact paragraph 1(o) entry and extensions. S.I. No. 405/2025 added other substances to Schedules 1 and 4 without amending paragraph 1(o). S.I. Nos. 9/2026 and 139/2026 amended Garda terminology and record-keeping/electronic-prescription provisions, respectively, without amending Schedule 1; S.I. No. 9/2026 states the collective citation is the Misuse of Drugs Regulations 2017 to 2026, and S.I. No. 139/2026 states that the collective citation includes it and commenced on 30 June 2026.

Israel’s Dangerous Drugs Ordinance [New Version], 5733–1973, covers 2-aminoindane through its First Schedule framework. An official Israel Anti-Drug Authority publication states that the Ordinance was expanded in 2011 to include the 2-aminoindan family, so qualifying structural derivatives are covered rather than only a single named molecule. The government’s 2014 Free Import Order separately places “2-amino-indane” in its Fourth Appendix list of dangerous and psychotropic drugs and notes that chemical derivatives defined by the Ordinance are included.

The current MHLW list expressly includes indan-2-amine and its salts (2-AI), designated on 12 December 2007. Japan prohibits import, manufacture, sale, possession and use of designated drugs except statutory medical/research uses.

The Netherlands places substances derived from 2-phenethylamine in List IA, and the group's structure-element B expressly includes substitutions that can lead to ring closure with structure element A. 2-Aminoindane has that ring-closed 2-phenethylamine framework and is therefore covered by the generic List IA group rather than requiring a name listing. Article 2a prohibits importing, exporting, preparing, processing, selling, supplying, transporting, possessing, or manufacturing substances in a List IA group, subject to statutory exceptions.

As of 26 August 2026, the official Polish schedule covers 2-aminoindane through the exact listed synonym 2-indanoamina (2A-I) and the corresponding structural/chemical designation 2,3-dihydro-1H-inden-2-amina in Annex 1, Group I-P. Under Article 33(2) of the Act on Counteracting Drug Addiction, Group I-P psychotropic substances may be used only for research. Article 34(1) limits possession of psychotropic substances to an authorized entrepreneur, organizational unit, or individual under the Act or the specified EU regulations. The 30 April 2025 amendment changes Group I-P item 7 and adds other entries, but does not amend item 1/2A-I. The 7 July 2026 amendment expressly identifies the underlying regulation as Dz.U. 2024 poz. 1139 and Dz.U. 2025 poz. 598, changes other schedule entries, and does not amend item 1/2A-I; it was published on 13 July 2026 and its 14-day commencement rule makes it effective on 28 July 2026. The latest Act amendment, Dz.U. 2026 poz. 1004, was not yet effective on 26 August 2026 and does not amend Articles 33 or 34. The prohibited status is therefore the schedule-based legal classification, subject to the research-use and authorized-possession limits.

Portugal lists 2-aminoindano (2,3-di-hidro-1H-inden-2-amina; or 1-aminoindan (2,3-di-hidro-1H-inden-1-amina)) as a new psychoactive substance in the annex republished by Portaria n.º 232/2022. Under Decreto-Lei n.º 54/2013, producing, importing, exporting, advertising, distributing, selling, possessing, or making listed new psychoactive substances available is prohibited, except for properly authorized industrial or pharmaceutical uses. The decree applies the Portuguese own-consumption framework to possession for mere personal consumption.

Resolution No. 1002 places this exact designation in List I, whose heading states that circulation in the Russian Federation is prohibited. The 2025 official amendment, Resolution No. 880, identifies the controlled-substances list as the list approved by Resolution No. 681. Resolution No. 1002 sets thresholds for this entry of over 0.05 g (significant), over 0.25 g (large), and over 500 g (especially large) for the specified Criminal Code provisions. The derivative coverage is limited to derivatives not included as separate positions.

The current Singapore Statutes Online consolidation places 2,3-Dihydro-1H-inden-2-amine (also known as 2-Aminoindane) at First Schedule Part 1, paragraph 18, item (31), under CLASS A DRUGS. Paragraph 18's chapeau covers the listed compounds, their salts and stereoisomeric forms, and preparations or products containing them. Section 2 defines a controlled drug as a substance or product specified in Part 1, 2 or 3 of the First Schedule (or anything containing one). S 323 states that it came into operation on 1 May 2014 and substituted Part I of the First Schedule; its original paragraph 18 item (11) expressly listed this substance. Subsequent schedule amendments inserted other items, and the current listing is item (31). First Schedule amendment S 321/2026 does not remove or alter it.

2-Aminoindane is the ring-closed indane analogue identified by PubChem CID 76310 as 2,3-dihydro-1H-inden-2-amine (SMILES C1C(CC2=CC=CC=C21)N). The official consolidated schedule dated 01 August 2025 places beta-aminopropylbenzene and beta-aminoisopropylbenzene derivatives in Schedule 6 where structurally derived by side-chain substitution or ring closure. SAHPRA's current first-party page identifies the July 2026 Consolidated Schedules (Version 1, date updated 06/07/2026) as the latest version and marks the August 2025 PDF archived and DO NOT USE. SAHPRA's amended-schedules index identifies Government Notice 7446 (Government Gazette 54627, 08/05/2026) as the latest amendment; the official Gazette text amends Schedule 4 only by inserting yohimbine for veterinary use and does not amend Schedule 6. Accordingly, the explicit Schedule 6 ring-closure clause remains in the current July 2026 consolidation.

Sweden's current consolidated Förordning (1992:1554) om kontroll av narkotika lists 2,3-dihydro-1H-inden-2-amin (2-aminoindan) in bilaga 1 under Centralstimulerande medel. Section 2 provides that substances in bilaga 1 are narcotics under the Narcotics Penal Act (1968:64). SFS 2020:2 added the listing and entered into force on 11 February 2020. The listing names only the substance and does not provide broader derivative or ester coverage.

Türkiye places 2-aminoindane (2,3-dihydro-1H-inden-2-amine) under Law No. 2313 through the annex to Cabinet Decision No. 2013/5742, published in Resmî Gazete No. 28893 on 25 January 2014. The official 2014 national drug report reproduces that annex and lists 2-aminoindane as item 85. The listing subjects the substance to the controls of the 2313 narcotics law.

Prohibited under the Psychoactive Substances Act 2016, which came into effect on May 26, 2016. Production, supply, and importation are criminal offenses.

The current Alabama Administrative Code Chapter 420-7-2 controlled-substances list expressly names 2-aminoindane and the synonym 2-AI, with state control dated March 18, 2014; the chapter's amendment history is current through April 9, 2026. The current DEA controlled-substance reference (August 2026) contains no aminoindane match and warns that its lists are not comprehensive. Under federal law, 21 U.S.C. § 802(32) defines controlled-substance analogues by specified tests, and § 813 treats a qualifying analogue as Schedule I to the extent intended for human consumption. Those federal provisions do not themselves make a substance an analogue without a fact-specific determination.

Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics legislation.